Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients

Haemophilia - Tập 13 Số 5 - Trang 533-541 - 2007
Donald F. Brophy1, Erika G. Martin1, Melinda E. Nolte2, Janice Kuhn2, Marcus E. Carr3
1Coagulation Special Studies Laboratory, Department of Pharmacy of Virginia Commonwealth University, Richmond, VA
2Central Virginia Center for Coagulation Disorders, Virginia Commonwealth University/Medical College of Virginia Campus, Richmond, VA, USA
3Novo Nordisk Research U.S., North Brunswick, NJ, USA

Tóm tắt

Summary.  NN1731 is a novel variant of recombinant factor VIIa (rFVIIa) that binds to activated platelets, but has greater enzymatic activity than rFVIIa in generating FXa and thrombin. The effect of NN1731 on clot structure and platelet function was characterized ex vivo in whole blood from healthy volunteers and haemophilic patients. Blood samples from six healthy volunteers, nine haemophilia A patients with and without inhibitors and one acquired haemophilia A patient, were spiked with increasing concentrations (0.32, 0.64 and 1.28 μg mL−1) of rFVIIa and NN1731. Platelet contractile force (PCF) or platelet function, clot elastic modulus (CEM) or clot structure, and force onset time (FOT) or the thrombin generation time (TGT) were determined using the Hemodyne Hemostasis Analysis System (HAS™). Baseline PCF, CEM and FOT values in patients were abnormal compared to healthy volunteers’ baseline values. Overall, haemophilia blood samples with or without inhibitors spiked with NN1731 had significantly greater PCF, CEM and shorter FOT values relative to samples spiked with corresponding doses of rFVIIa. The variability in response to treatment between patients was greater with rFVIIa compared to NN1731. At 1.28 μg mL−1 (90 μg kg−1), NN1731 normalized PCF, CEM and FOT in nine of 10 patients, while rFVIIa normalized these parameters in four of 10 patients. Increasing in vitro concentrations of NN1731 normalized platelet function, clot structure and thrombin generation consistently in haemophilia blood with or without inhibitors. NN1731 may be a promising haemostatic agent for patients with bleeding disorders. These results should be confirmed in an in vivo study.

Từ khóa


Tài liệu tham khảo

10.1111/j.1365-2516.2006.01261.x

10.1046/j.1365-2516.2003.00780.x

10.2165/00003495-200565080-00008

10.1016/j.jbiotec.2006.03.042

10.1182/blood.V99.3.923

Hoffman M, 1998, Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high‐dose activated factor VII, Blood Coagul Fibrinolysis, 9, S61

10.1046/j.1365-2141.1997.4463256.x

10.1016/S0140-6736(03)13405-8

10.1111/j.1365-2516.2004.00924.x

10.1042/BJ20031596

10.1053/j.seminhematol.2003.11.017

10.1073/pnas.241339498

10.1161/01.ATV.0000257204.82396.2b

10.1111/j.1365-2141.2007.06534.x

10.1182/blood-2003-05-1369

10.1046/j.1538-7836.2003.00337.x

10.1385/CBB:38:1:55

Carr ME, 2004, Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa, Clin Lab, 505, 29

Kasper CK, 1975, Proceedings: a more uniform measurement of factor VIII inhibitors, Thromb Diath Haemorrh, 34, 612

Carr ME, 2003, Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion, Thromb Haemost, 89, 803, 10.1055/s-0037-1613465

10.1111/j.1538-7836.2007.02308.x

Thông tin
Thông tin xuất bản

Haemophilia

Tập 13 Số 5

533-541

Thông tin tác giả